Topics:

Rheumatoid Arthritis

Rheumatoid Arthritis

(CCR2015) Nearly 100 new molecules are in development as RA treatments. This summary of a recent presentation by the ever-eloquent Ed Keystone MD gives a brief rundown of their mechanisms, progress, and potential.

rheumatoid arthritis

(CCR 2015) A new rheumatoid arthritis (RA) research center in the UK intends to revolutionize the understanding and treatment of the rheumatoid arthritis by 2020 by using systems biology to move beyond the one-molecule paradigm.

rheumatoid arthritis

One very targeted clue to treatment failure: An observational study from Israel identifies Sephardic Jews as more likely than Ashkenazim to form antibodies against the biologic drug infliximab.

rheumatoid arthritis

In the second installment of a slide show based on an animated discussion by members of the rheumatology journal club (#rheumjc), partipants focus on the benefits, risks, and realities of tapering biologics in clinical practice.

rheumatoid arthritis

Slides summarize of a Twitter-based journal club, pondering a randomized study of tapering TNF inhibitors in rheumatoid arthritis. Many questions about the study design; more about tapering practices already in clinical use, which are addressed in Part 2.

A meta-analysis involving more than 40,000 patients finds that biologics have a 30% increased infection risk compared to DMARDs, which is greatest for patients who have also used methotrexate.

A new app-based registry focusing on rheumatoid and psoriatic arthritis and ankylosing spondylitis aims to use patient-generated data to resolve important unanswered clinical questions. Its rheumatologist sponsor urges you to encourage patients to join up.

Pages

Subscribe to Rheumatoid Arthritis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.